n(g),n(g')-dimethyl-l-arginine and Atherogenesis studies

N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine

Research Excerpts

Excerpt	Relevance	Reference
" Hyperleptinemia has been linked with the development of hypertension and endothelial dysfunction/atherosclerosis, two main pathophysiological conditions associated with cardiovascular disease development."	8.93	Pathophysiological Role of Adiponectin, Leptin and Asymmetric Dimethylarginine in the Process of Atherosclerosis. ( Deneva, TI; Koleva, DI; Nikolova, JG; Orbetzova, MM, 2016)
"BET supplementation may be effective in preventing hyperlipidemia, disturbed NO availability, oxidative stress, and the development of fatty liver and atherosclerotic lesions that might result from excess amounts of cholesterol and methionine in the diet."	7.88	Effects of betaine supplementation on nitric oxide metabolism, atherosclerotic parameters, and fatty liver in guinea pigs fed a high cholesterol plus methionine diet. ( Bekpınar, S; Çevik, A; Genc, S; Gürdöl, F; Küskü-Kiraz, Z; Olgaç, V; Ünlücerci, Y; Uysal, M, 2018)
"We aimed to evaluate asymmetric dimethylarginine levels in young patients with Type 1 diabetes mellitus according to diabetes duration and to examine the relationship between these levels and measures of atherosclerosis and myocardial function."	7.88	Asymmetric dimethylarginine levels and diabetes duration: Relationship with measures of subclinical atherosclerosis and cardiac function in children and adolescents with Type 1 diabetes. ( Çetin, M; Coşkun, Ş; Eroğlu, N; Ersoy, B; Onur, E; Özkol, M, 2018)
"ABI = ankle-brachial index Apo = apolipoprotein ADMA = asymmetric dimethylarginine BMI = body mass index CVD = cardiovascular disease CIMT = carotid intima-media thickness CS = Cushing syndrome DM = diabetes mellitus DDAH = dimethylarginine dimethylaminohydrolase ELISA = enzyme-linked immunosorbent assay HDL = high-density lipoprotein hsCRP = high-sensitive C-reactive protein HOMA-IR = homeostatic model assessment of insulin resistance HT = hypertension LDL = low-density lipoprotein Lp-PLA2 = lipoprotein-associated phospholipase A2 Lp-a = lipoprotein a NO = nitric oxide."	7.83	ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME. ( Akturk, M; Altinova, AE; Arslan, E; Gulbahar, O; Ozkan, C; Ozsurekci, CG; Toruner, F; Yalcin, M, 2016)
" Since thyroid hormones may mediate the association between ARG derivatives and atherosclerosis, this study investigated whether asymmetric and symmetric dimethylarginines (ADMA and SDMA, respectively) as well as homoarginine (hARG) are associated with parameters of thyroid function in the general population."	7.83	L-Arginine Derivatives Are Associated with the Hyperthyroid State in the General Population. ( Atzler, D; Bahls, M; Böger, RH; Dörr, M; Felix, SB; Friedrich, N; Ittermann, T; Schwedhelm, E; Völzke, H, 2016)
"This study was to assess the relationship between asymmetric dimethylarginine (ADMA) and carotid atherosclerosis in patients with essential hypertension."	7.81	Asymmetric dimethylarginine is associated with carotid atherosclerosis in patients with essential hypertension. ( Wang, X; Xia, W; Xu, L; Xu, W; Yao, Y, 2015)
"The aim of this study was to assess the atherogenicity risk of antiepileptics in children by investigating the cascade, "hyperhomocysteinemia (HHcy)→asymmetric dimethylarginine (ADMA) increase→nitric oxide (NO) decrease", which is thought to contribute to the developmental process of atherosclerosis."	7.79	Assessment of atherosclerosis risk due to the homocysteine-asymmetric dimethylarginine-nitric oxide cascade in children taking antiepileptic drugs. ( Arga, M; Arhan, E; Biberoglu, G; Cansu, A; Emeksiz, HC; Gulbahar, O; Hasanoglu, A; Serdaroglu, A, 2013)
"To identify the presence of subclinical atherosclerosis in patients with psoriatic arthritis (PsA) and healthy controls using intima-media thickness (IMT), coronary flow reserve (CFR), and the plasma concentration of asymmetric dimethylarginine (ADMA), to evaluate the correlations among ADMA, IMT, and CFR."	7.77	Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. ( Atzeni, F; Battellino, M; Boccassini, L; De Gennaro Colonna, V; Gianturco, L; Marchesoni, A; Sarzi-Puttini, P; Sitia, S; Tomasoni, L; Turiel, M, 2011)
"To observe the effect of Xuefu Zhuyu decoction on serum asymmetric dimethylarginine (ADMA) level of the atherosclerosis rabbits."	7.75	[Effects of Xuefu Zhuyu decoction on serum asymmetric dimethylarginine in atherosclerosis rabbits]. ( Jiang, H; Li, Y; Lin, G; Zeng, H; Zhao, A, 2009)
"Asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase (eNOS), is considered to be a risk factor for atherosclerosis."	7.75	Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. ( Antoniades, C; Antonopoulos, A; Channon, KM; Cunnington, C; Leeson, P; Pillai, R; Ratnatunga, C; Shirodaria, C; Stefanadis, C; Tousoulis, D; Van-Assche, T; Warrick, N, 2009)
"Asymmetrical dimethylarginine (ADMA) was found to be increased in conditions associated with atherosclerosis and metabolic disorders."	7.74	Asymmetric dimethylarginine (ADMA) is tightly correlated with growth in juveniles without correlations to obesity related disorders. ( Almer, G; Gasser, R; Gruber, HJ; Horejsi, R; Mangge, H; März, W; Mayer, C; Meinitzer, A; Möller, R; Pilz, S; Truschnig-Wilders, M, 2008)
"We tested if asymmetric dimethylarginine (ADMA) contributes to the simultaneous evolution of atherosclerosis and insulin resistance."	7.74	Dimethylarginines at the crossroad of insulin resistance and atherosclerosis. ( Bereczki, D; Csiba, L; Gesztelyi, R; Kéki, S; Lenkei, A; Magyar, MT; Török, J; Valikovics, A; Zsuga, J; Zsuga, M, 2007)
"Asymmetric dimethylarginine (ADMA) assumes a significant role in atherosclerosis by inhibiting the endothelial nitric oxide synthase (eNOS)."	7.74	Serum asymmetric dimethylarginine negatively correlates with intima-media thickness in early-onset atherosclerosis. ( Bereczki, D; Csiba, L; Gesztelyi, R; Kéki, S; Magyar, MT; Torok, J; Valikovics, A; Zsuga, J; Zsuga, M, 2007)
"Homocysteine (Hcy) and asymmetric dimethylarginine (ADMA) recently were recognized as potential risk factors for atherosclerosis in the general population, and the metabolism of each of these substances seems to be closely related."	7.73	Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. ( Hishida, A; Ikegaya, N; Kato, A; Kumagai, H; Maruyama, Y; Sakurai, M; Takita, T; Uno, S, 2006)
"Dyslipidemia was defined as total cholesterol levels ≥200 mg/dL and/or triglyceride level ≥150 mg/dL."	5.40	Comparison of plasma viscosity as a marker of endothelial dysfunction with nitric oxide and asymmetric dimethylarginine in subjects with dyslipidemia. ( Ercan, M; Firtina, S; Konukoglu, D, 2014)
" Hyperleptinemia has been linked with the development of hypertension and endothelial dysfunction/atherosclerosis, two main pathophysiological conditions associated with cardiovascular disease development."	4.93	Pathophysiological Role of Adiponectin, Leptin and Asymmetric Dimethylarginine in the Process of Atherosclerosis. ( Deneva, TI; Koleva, DI; Nikolova, JG; Orbetzova, MM, 2016)
" Nowadays, homoarginine (hArg) is considered as a new key player in atherogenesis."	4.91	Homoarginine in the shadow of asymmetric dimethylarginine: from nitric oxide to cardiovascular disease. ( Androulakis, E; Antoniades, C; Papageorgiou, N; Papaioannou, S; Tousoulis, D, 2015)
" The aim of this study was to examine associations between asymmetric dimethylarginine (ADMA) - a biomarker of atherosclerosis - and assessments of macrovascular endothelial function in patients with SSc."	4.31	The role of asymmetric dimethylarginine in endothelial dysfunction and abnormal nitric oxide metabolism in systemic sclerosis: results from a pilot study. ( Dimitroulas, T; Doumas, M; Garyfallos, A; Karagiannis, A; Katsiki, N; Kitas, G; Loutradis, C; Malliari, A; Pagkopoulou, E; Soulaidopoulos, S, 2023)
" Asymmetric dimethyl arginine (ADMA) levels promote the development of endothelial dysfunction and atherosclerosis-related diseases such as hypertension, acute coronary syndrome, congestive heart failure, and peripheral vascular diseases."	3.91	Assessment of Endothelial Dysfunction with Methylated Arginines and L-arginine in Cadmium-Exposed People: a Pilot Study. ( Cetintepe, SP; Deniz, S; Gunduzoz, M; Iritas, SB; Oztan, O; Tekin, G; Turksoy, VA; Tutkun, L; Unlu, A, 2019)
"Our results suggest that endothelial dysfunction starts in the early stage of adolescent vitamin B12 deficiency, and vitamin B12-deficient adolescents have increased circulating asymmetric dimethylarginine, showing that endothelial dysfunction and increased carotid artery intima media thickness be related to atherosclerosis."	3.91	Increased asymmetric dimethylarginine in vitamin B12 deficient adolescents. ( Çelik, SF; Dündar, MA; Karakükçü, Ç; Tartıcı, EK; Torun, YA, 2019)
"BET supplementation may be effective in preventing hyperlipidemia, disturbed NO availability, oxidative stress, and the development of fatty liver and atherosclerotic lesions that might result from excess amounts of cholesterol and methionine in the diet."	3.88	Effects of betaine supplementation on nitric oxide metabolism, atherosclerotic parameters, and fatty liver in guinea pigs fed a high cholesterol plus methionine diet. ( Bekpınar, S; Çevik, A; Genc, S; Gürdöl, F; Küskü-Kiraz, Z; Olgaç, V; Ünlücerci, Y; Uysal, M, 2018)
"We aimed to evaluate asymmetric dimethylarginine levels in young patients with Type 1 diabetes mellitus according to diabetes duration and to examine the relationship between these levels and measures of atherosclerosis and myocardial function."	3.88	Asymmetric dimethylarginine levels and diabetes duration: Relationship with measures of subclinical atherosclerosis and cardiac function in children and adolescents with Type 1 diabetes. ( Çetin, M; Coşkun, Ş; Eroğlu, N; Ersoy, B; Onur, E; Özkol, M, 2018)
" The aim of this study was to investigate the relationship between brachial intima-media thickness (B-IMT), an independent predictor of cardiovascular risk, systemic inflammation, and asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, in patients with COPD and respective controls."	3.85	Increased brachial intima-media thickness is associated with circulating levels of asymmetric dimethylarginine in patients with COPD. ( Burghuber, OC; Eickhoff, P; Funk, GC; Urban, MH; Valipour, A; Wolzt, M, 2017)
"ABI = ankle-brachial index Apo = apolipoprotein ADMA = asymmetric dimethylarginine BMI = body mass index CVD = cardiovascular disease CIMT = carotid intima-media thickness CS = Cushing syndrome DM = diabetes mellitus DDAH = dimethylarginine dimethylaminohydrolase ELISA = enzyme-linked immunosorbent assay HDL = high-density lipoprotein hsCRP = high-sensitive C-reactive protein HOMA-IR = homeostatic model assessment of insulin resistance HT = hypertension LDL = low-density lipoprotein Lp-PLA2 = lipoprotein-associated phospholipase A2 Lp-a = lipoprotein a NO = nitric oxide."	3.83	ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME. ( Akturk, M; Altinova, AE; Arslan, E; Gulbahar, O; Ozkan, C; Ozsurekci, CG; Toruner, F; Yalcin, M, 2016)
" We hypothesized that soluble receptor for advanced glycation end products (sRAGE) and asymmetric dimethyl arginine (ADMA) can correlate with carotid intima-media thickness (cIMT), a known index of subclinical atherosclerosis."	3.83	Soluble receptor and gene polymorphism for AGE: relationship with obesity and cardiovascular risks. ( Aly, H; El Melegy, S; El Shikh, T; El-Batch, M; Rowisha, M, 2016)
" Since thyroid hormones may mediate the association between ARG derivatives and atherosclerosis, this study investigated whether asymmetric and symmetric dimethylarginines (ADMA and SDMA, respectively) as well as homoarginine (hARG) are associated with parameters of thyroid function in the general population."	3.83	L-Arginine Derivatives Are Associated with the Hyperthyroid State in the General Population. ( Atzler, D; Bahls, M; Böger, RH; Dörr, M; Felix, SB; Friedrich, N; Ittermann, T; Schwedhelm, E; Völzke, H, 2016)
"This study was to assess the relationship between asymmetric dimethylarginine (ADMA) and carotid atherosclerosis in patients with essential hypertension."	3.81	Asymmetric dimethylarginine is associated with carotid atherosclerosis in patients with essential hypertension. ( Wang, X; Xia, W; Xu, L; Xu, W; Yao, Y, 2015)
"The purpose of the work was to study the impact of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA) and its degrading enzyme, dimethylarginine dimethylaminohydrolase (DDAH1), on atherosclerosis in subtotally nephrectomized (SNX) ApoE-deficient mice."	3.80	Effect of lowering asymmetric dimethylarginine (ADMA) on vascular pathology in atherosclerotic ApoE-deficient mice with reduced renal mass. ( Arend, M; Cordasic, N; Hilgers, KF; Jacobi, J; Maas, R, 2014)
"The aim of this study was to assess the atherogenicity risk of antiepileptics in children by investigating the cascade, "hyperhomocysteinemia (HHcy)→asymmetric dimethylarginine (ADMA) increase→nitric oxide (NO) decrease", which is thought to contribute to the developmental process of atherosclerosis."	3.79	Assessment of atherosclerosis risk due to the homocysteine-asymmetric dimethylarginine-nitric oxide cascade in children taking antiepileptic drugs. ( Arga, M; Arhan, E; Biberoglu, G; Cansu, A; Emeksiz, HC; Gulbahar, O; Hasanoglu, A; Serdaroglu, A, 2013)
"Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, plays a role in endothelial dysfunction, an initial step of atherosclerosis."	3.79	Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction. ( Ando, R; Fukami, K; Kaida, Y; Kaifu, K; Miyazaki, H; Nakayama, Y; Obara, N; Okuda, S; Takeuchi, M; Ueda, S; Yamagishi, S; Yokoro, M, 2013)
"Arsenic exposure is a risk factor for atherosclerosis in adults, but there is little information on arsenic and early risk biomarkers for atherosclerosis in children."	3.79	Carotid intima-media thickness and plasma asymmetric dimethylarginine in Mexican children exposed to inorganic arsenic. ( Aguilar-Madrid, G; Arreola-Mendoza, L; Ayllon-Vergara, JC; Barrera-Hernández, A; De Vizcaya-Ruiz, A; Del Razo, LM; Hernández-Castellanos, E; Osorio-Yáñez, C, 2013)
"To identify the presence of subclinical atherosclerosis in patients with psoriatic arthritis (PsA) and healthy controls using intima-media thickness (IMT), coronary flow reserve (CFR), and the plasma concentration of asymmetric dimethylarginine (ADMA), to evaluate the correlations among ADMA, IMT, and CFR."	3.77	Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. ( Atzeni, F; Battellino, M; Boccassini, L; De Gennaro Colonna, V; Gianturco, L; Marchesoni, A; Sarzi-Puttini, P; Sitia, S; Tomasoni, L; Turiel, M, 2011)
"Elevated blood concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric-oxide (NO) synthase, are found in association with diabetes, hypertension, congestive heart failure, and atherosclerosis."	3.76	Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. ( Lentz, SR; Murry, DJ; Rodionov, RN; Stevens, JW; Vaulman, SF, 2010)
"We compared plasma markers of endothelial dysfunction, asymmetric dimethylarginine (ADMA) and endothelin-1 (ET-1), and atherosclerosis progression (soluble fraction of the CD40 ligand, sCD40L) in OSAS patients with (n = 23) and without (n = 18) concurrent CV risk factors, as well as in healthy subjects (n = 23)."	3.75	Increased plasma levels of asymmetric dimethylarginine and soluble CD40 ligand in patients with sleep apnea. ( Agustí, AG; Alonso, A; Ayllón, O; Barceló, A; de la Peña, M; González, C; Pérez, G; Piérola, J; Vega-Agapito, MV, 2009)
"Asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase (eNOS), is considered to be a risk factor for atherosclerosis."	3.75	Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. ( Antoniades, C; Antonopoulos, A; Channon, KM; Cunnington, C; Leeson, P; Pillai, R; Ratnatunga, C; Shirodaria, C; Stefanadis, C; Tousoulis, D; Van-Assche, T; Warrick, N, 2009)
"To observe the effect of Xuefu Zhuyu decoction on serum asymmetric dimethylarginine (ADMA) level of the atherosclerosis rabbits."	3.75	[Effects of Xuefu Zhuyu decoction on serum asymmetric dimethylarginine in atherosclerosis rabbits]. ( Jiang, H; Li, Y; Lin, G; Zeng, H; Zhao, A, 2009)
"Asymmetrical dimethylarginine (ADMA) was found to be increased in conditions associated with atherosclerosis and metabolic disorders."	3.74	Asymmetric dimethylarginine (ADMA) is tightly correlated with growth in juveniles without correlations to obesity related disorders. ( Almer, G; Gasser, R; Gruber, HJ; Horejsi, R; Mangge, H; März, W; Mayer, C; Meinitzer, A; Möller, R; Pilz, S; Truschnig-Wilders, M, 2008)
"This study was designed to determine the relationship between plasma asymmetric dimethylarginine (ADMA) and the development of carotid atherosclerosis."	3.74	Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: six-year prospective study using carotid ultrasonography. ( Adachi, H; Enomoto, M; Fukami, A; Furuki, K; Imaizumi, T; Kakuma, T; Kumagae, S; Matsuoka, H; Nanjo, Y; Otsuka, M, 2008)
"We tested if asymmetric dimethylarginine (ADMA) contributes to the simultaneous evolution of atherosclerosis and insulin resistance."	3.74	Dimethylarginines at the crossroad of insulin resistance and atherosclerosis. ( Bereczki, D; Csiba, L; Gesztelyi, R; Kéki, S; Lenkei, A; Magyar, MT; Török, J; Valikovics, A; Zsuga, J; Zsuga, M, 2007)
"Asymmetric dimethylarginine (ADMA) assumes a significant role in atherosclerosis by inhibiting the endothelial nitric oxide synthase (eNOS)."	3.74	Serum asymmetric dimethylarginine negatively correlates with intima-media thickness in early-onset atherosclerosis. ( Bereczki, D; Csiba, L; Gesztelyi, R; Kéki, S; Magyar, MT; Torok, J; Valikovics, A; Zsuga, J; Zsuga, M, 2007)
"Asymmetric dimethylarginine (ADMA) is a naturally occurring inhibitor of nitric oxide synthesis that accumulates in a wide range of diseases associated with endothelial dysfunction and enhanced atherosclerosis."	3.73	Effects of ADMA upon gene expression: an insight into the pathophysiological significance of raised plasma ADMA. ( Anthony, S; Hubank, M; Leiper, JM; Smith, CL; Vallance, P, 2005)
"We investigated whether the eNOS G/T polymorphism (Glu298Asp variant) is linked to the severity of carotid atherosclerosis and whether it is independent of asymmetric dimethylarginine (ADMA) in determining vascular damage in patients with end-stage renal disease (ESRD)."	3.73	Atherosclerosis and the Glu298Asp polymorphism of the eNOS gene in white patients with end-stage renal disease. ( Benedetto, FA; Boeger, RH; Maas, R; Mallamaci, F; Parlongo, RM; Pisano, A; Spoto, B; Testa, A; Tripepi, G; Zoccali, C, 2005)
"Homocysteine (Hcy) and asymmetric dimethylarginine (ADMA) recently were recognized as potential risk factors for atherosclerosis in the general population, and the metabolism of each of these substances seems to be closely related."	3.73	Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. ( Hishida, A; Ikegaya, N; Kato, A; Kumagai, H; Maruyama, Y; Sakurai, M; Takita, T; Uno, S, 2006)
"In study II, 41 patients with type 2 diabetes and mild hyperhomocysteinaemia were analysed after 6 months treatment with 5 mg of folic acid or placebo."	2.72	No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk. ( Brouwer, CB; Rauwerda, JA; Smulders, YM; Spoelstra-de Man, AM; Stehouwer, CD; Teerlink, T, 2006)
" NO bioavailability indicates the production and utilization of endothelial NO in organisms, its decrease is related to oxidative stress, lipid infiltration, the expressions of some inflammatory factors and the alteration of vascular tone, which plays an important role in endothelial dysfunction."	2.58	Nitric oxide bioavailability dysfunction involves in atherosclerosis. ( Chang, J; Chen, JY; Hong, FF; Wang, XF; Yang, MW; Yang, SL; Ye, ZX; Zhong, HH, 2018)
" In principle, it is caused by an impaired bioavailability of nitric oxide (NO) due to an inhibited synthesis (eg, by asymmetric dimethylarginine [ADMA]) or increased consumption of formed NO (by reactive oxygen species [ROS])."	2.44	Roles of oxidants, nitric oxide, and asymmetric dimethylarginine in endothelial function. ( Grammer, T; März, W; Siekmeier, R, 2008)
"This case-cohort study included Chronic Renal Insufficiency Cohort participants with baseline diabetes, estimated glomerular filtration rate <60 mL/min/1."	1.91	Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. ( Anderson, AH; Bhat, Z; Brown, J; Brunengraber, H; Charleston, J; Chen, J; Feldman, HI; He, J; Hostetter, TH; Hsu, CY; Ix, JH; Kimmel, PL; Mehta, R; Rao, P; Sapa, H; Schelling, JR; Schrauben, SJ; Seegmiller, JC; Shafi, T; Shlipak, MG; Townsend, R; Vasan, RS; Xie, D; Zhang, X, 2023)
"Patients with type 2 diabetes represent 50% of all sudden cardiac deaths."	1.62	Lack of evidence of the correlation between plasma Asymmetrical Dimethylarginine correlation and IMT in type 2 diabetic patients with chronic vascular complication. ( Adamiec, R; Dumas, I; Fiodorenko-Dumas, Z; Małecki, R; Paprocka-Borowicz, M; Rabczynski, M, 2021)
"Dyslipidemia was defined as total cholesterol levels ≥200 mg/dL and/or triglyceride level ≥150 mg/dL."	1.40	Comparison of plasma viscosity as a marker of endothelial dysfunction with nitric oxide and asymmetric dimethylarginine in subjects with dyslipidemia. ( Ercan, M; Firtina, S; Konukoglu, D, 2014)
"Our data suggested that NAFLD is associated with endothelial dysfunction and increased earlier in patients with atherosclerosis compared to control subjects."	1.39	Assessment of endothelial function in patients with nonalcoholic fatty liver disease. ( Colak, Y; Coskunpinar, E; Doganay, L; Kahraman, OT; Mesci, B; Ozturk, O; Senates, E; Tuncer, I; Ulasoglu, C; Yesil, A; Yilmaz, Y, 2013)
"Nonalcoholic fatty liver disease (NAFLD), a hepatic manifestation of metabolic syndrome (MetS) is closely associated with an increased risk of cardiovascular disease."	1.39	Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. ( Aslan, F; Bagci, S; Dogru, T; Ercin, CN; Genc, H; Kara, M; Karslioglu, Y; Kurt, I; Ors, F; Sertoglu, E; Sonmez, A; Tapan, S, 2013)
"Because UTN accumulates in patients with chronic renal failure, the association between plasma UTN and biomarkers of atherosclerosis and endothelial activation needs to be better understood."	1.33	Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. ( Cutrupi, S; Mallamaci, F; Pizzini, P; Tripepi, G; Zoccali, C, 2006)

Research

Studies (100)

Authors

Clinical Trials (9)

Trial Overview

Trial Outcomes

Diastolic Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 Between the Groups

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	34 (34.00)	29.6817
2010's	57 (57.00)	24.3611
2020's	9 (9.00)	2.80

Authors	Studies
Okada, A	1
Murata, T	1
Matin, K	1
Ariyoshi, M	1
Otsuka, R	1
Yamashita, M	1
Suzuki, M	2
Wakiyama, R	1
Tateno, K	1
Aoyagi, H	1
Uematsu, H	1
Imamura, A	1
Kosaka, M	1
Mizukaki, T	1
Sato, T	1
Kawahara, H	1
Hanada, N	1
Papageorgiou, N	3
Theofilis, P	2
Oikonomou, E	2
Lazaros, G	2
Sagris, M	2
Tousoulis, D	4
Pagkopoulou, E	1
Soulaidopoulos, S	1
Katsiki, N	1
Malliari, A	1
Loutradis, C	1
Karagiannis, A	1
Doumas, M	1
Garyfallos, A	1
Kitas, G	1
Dimitroulas, T	2
Schrauben, SJ	1
Sapa, H	1
Xie, D	1
Zhang, X	1
Anderson, AH	1
Shlipak, MG	1
Hsu, CY	1
Shafi, T	1
Mehta, R	1
Bhat, Z	1
Brown, J	1
Charleston, J	1
Chen, J	1
He, J	2
Ix, JH	1
Rao, P	1
Townsend, R	1
Kimmel, PL	1
Vasan, RS	2
Feldman, HI	1
Seegmiller, JC	1
Brunengraber, H	1
Hostetter, TH	1
Schelling, JR	1
Tutkun, L	1
Gunduzoz, M	1
Turksoy, VA	1
Deniz, S	1
Oztan, O	1
Cetintepe, SP	1
Iritas, SB	1
Tekin, G	1
Unlu, A	1
Yang, D	1
Yang, Z	1
Chen, L	1
Kuang, D	1
Zou, Y	1
Li, J	1
Deng, X	1
Luo, S	1
Luo, J	1
Yan, M	1
He, G	1
Deng, Y	1
Li, R	1
Yuan, Q	1
Zhou, Y	1
Jiang, P	1
Tan, S	1
Yilmaz, MI	1
Romano, M	1
Basarali, MK	1
Elzagallaai, A	1
Karaman, M	1
Demir, Z	1
Demir, MF	1
Akcay, F	1
Seyrek, M	1
Haksever, N	1
Piskin, D	1
Cimaz, R	1
Rieder, MJ	1
Demirkaya, E	1
Mangoni, AA	1
Tommasi, S	1
Sotgia, S	2
Zinellu, A	2
Paliogiannis, P	1
Piga, M	1
Cauli, A	1
Pintus, G	1
Carru, C	2
Erre, GL	2
Fiodorenko-Dumas, Z	1
Dumas, I	1
Rabczynski, M	1
Małecki, R	1
Adamiec, R	1
Paprocka-Borowicz, M	1
Lee, TS	1
Lu, TM	1
Chen, CH	1
Guo, BC	1
Hsu, CP	1
Chu, R	1
Yu, D	1
Chu, J	1
Lin, M	1
Yu, H	1
Li, D	1
Misialek, JR	1
Huang, F	1
Windham, GB	1
Yu, F	1
Alonso, A	2
Chen, JY	1
Ye, ZX	1
Wang, XF	1
Chang, J	1
Yang, MW	1
Zhong, HH	1
Hong, FF	1
Yang, SL	1
Küskü-Kiraz, Z	1
Genc, S	1
Bekpınar, S	1
Ünlücerci, Y	1
Çevik, A	1
Olgaç, V	1
Gürdöl, F	1
Uysal, M	1
Rzepecka-Stojko, A	1
Stojko, J	1
Jasik, K	1
Buszman, E	1
Wang, F	1
Xiong, R	1
Feng, S	1
Lu, X	1
Li, H	1
Wang, S	1
Ersoy, B	1
Eroğlu, N	1
Çetin, M	1
Onur, E	1
Özkol, M	1
Coşkun, Ş	1
Di Franco, M	1
Lucchino, B	1
Conti, F	1
Valesini, G	1
Spinelli, FR	1
Małyszko, J	1
Matuszkiewicz-Rowińska, J	1
Wieczór, AM	1
Wieczór, R	1
Kulwas, A	1
Rość, D	1
Doğan, İ	1
Eser, B	1
Özkurt, S	1
Yayar, Ö	1
Özgür, B	1
Kayadibi, H	1
Doğan, T	1
Muşmul, A	1
Soydan, M	1
Sozański, T	1
Kucharska, AZ	1
Wiśniewski, J	1
Fleszar, MG	1
Rapak, A	1
Gomułkiewicz, A	1
Dzięgiel, P	1
Magdalan, J	1
Nowak, B	1
Szumny, D	1
Matuszewska, A	1
Piórecki, N	1
Szeląg, A	1
Trocha, M	1
Dündar, MA	1
Torun, YA	1
Çelik, SF	1
Tartıcı, EK	1
Karakükçü, Ç	1
Kitas, GD	1
Ercan, M	1
Firtina, S	1
Konukoglu, D	2
Osorio-Yáñez, C	1
Ayllon-Vergara, JC	1
Aguilar-Madrid, G	1
Arreola-Mendoza, L	1
Hernández-Castellanos, E	1
Barrera-Hernández, A	1
De Vizcaya-Ruiz, A	1
Del Razo, LM	1
Ando, R	1
Ueda, S	1
Yamagishi, S	1
Miyazaki, H	1
Kaida, Y	1
Kaifu, K	1
Yokoro, M	1
Nakayama, Y	1
Obara, N	1
Fukami, K	1
Takeuchi, M	1
Okuda, S	1
Alonso-Bouzón, C	1
Carcaillon, L	1
García-García, FJ	1
Amor-Andrés, MS	1
El Assar, M	1
Rodríguez-Mañas, L	1
Locsey, L	1
Seres, I	1
Sztanek, F	1
Harangi, M	1
Padra, J	1
Kovacs, D	1
Fedor, R	1
Asztalos, L	1
Paragh, G	1
Chen, X	1
Lin, YN	1
Fang, DH	1
Zhang, HQ	1
Huang, WJ	1
Jacobi, J	2
Maas, R	4
Arend, M	2
Cordasic, N	2
Hilgers, KF	2
Celik, M	1
Cerrah, S	1
Arabul, M	1
Akalin, A	1
Xia, W	1
Xu, L	1
Xu, W	1
Wang, X	1
Yao, Y	1
Notsu, Y	1
Yano, S	1
Shibata, H	1
Nagai, A	1
Nabika, T	1
Yilmazer, B	1
Sahin, T	1
Unlu, BÖ	1
Kir, HM	1
Cefle, A	1
Androulakis, E	1
Papaioannou, S	1
Antoniades, C	2
Givvimani, S	1
Kundu, S	1
Pushpakumar, S	1
Doyle, V	1
Narayanan, N	1
Winchester, LJ	1
Veeranki, S	1
Metreveli, N	1
Tyagi, SC	1
Gilinsky, MA	1
Sukhovershin, RA	1
Cherkanova, MS	1
Ittermann, T	1
Bahls, M	1
Atzler, D	2
Friedrich, N	1
Schwedhelm, E	3
Böger, RH	3
Felix, SB	1
Völzke, H	1
Dörr, M	1
Solovyeva, LN	1
Shmonin, AA	1
Emanuel, YV	1
Stolyarov, MS	1
Bondareva, EA	1
Lazareva, NM	1
Kholopova, IV	1
Blinova, TV	1
Kharitonova, TV	1
Lapin, SV	1
Emanuel, VL	1
Melnikova, EV	1
Jiang, N	1
Wang, M	1
Song, J	1
Liu, Y	1
Chen, H	1
Mu, D	1
Xia, M	1
Rowisha, M	1
El-Batch, M	1
El Shikh, T	1
El Melegy, S	1
Aly, H	1
Ozsurekci, CG	1
Akturk, M	1
Ozkan, C	1
Gulbahar, O	2
Altinova, AE	1
Yalcin, M	1
Arslan, E	1
Toruner, F	1
Haissman, JM	1
Haugaard, AK	1
Knudsen, A	1
Kristoffersen, US	1
Seljeflot, I	1
Pedersen, KK	1
Lebech, AM	1
Hasbak, P	1
Kjær, A	1
Ostrowski, SR	1
Gerstoft, J	1
Trøseid, M	1
Nielsen, SD	1
Huang, S	1
Zou, D	1
Peng, W	1
Jiang, X	1
Shao, K	1
Xia, L	1
Tang, Y	1
Koleva, DI	1
Orbetzova, MM	1
Nikolova, JG	1
Deneva, TI	2
Ozalper, V	1
Kara, M	2
Tanoglu, A	1
Cetındaglı, I	1
Ozturker, C	1
Hancerlı, Y	1
Hıra, S	1
Kara, K	1
Beyazıt, Y	1
Yazgan, Y	1
Urban, MH	1
Eickhoff, P	1
Funk, GC	1
Burghuber, OC	1
Wolzt, M	1
Valipour, A	1
Haghikia, A	2
Yanchev, GR	1
Kayacelebi, AA	1
Hanff, E	1
Bledau, N	1
Widera, C	1
Sonnenschein, K	1
Weissenborn, K	1
Bauersachs, J	2
Bavendiek, U	1
Tsikas, D	2
Gruber, HJ	1
Mayer, C	1
Meinitzer, A	1
Almer, G	1
Horejsi, R	1
Möller, R	1
Pilz, S	1
März, W	2
Gasser, R	1
Truschnig-Wilders, M	1
Mangge, H	1
Vladimirova-Kitova, LG	1
Manukov, IH	1
Sirakova, I	1
Zsuga, J	4
Kato, A	2
Odamaki, M	1
Ishida, J	1
Hishida, A	2
Furuki, K	1
Adachi, H	1
Enomoto, M	1
Otsuka, M	1
Fukami, A	1
Kumagae, S	1
Matsuoka, H	1
Nanjo, Y	1
Kakuma, T	1
Imaizumi, T	1
Surdacki, A	1
Siekmeier, R	1
Grammer, T	1
Barceló, A	1
de la Peña, M	1
Ayllón, O	1
Vega-Agapito, MV	1
Piérola, J	1
Pérez, G	1
González, C	1
Agustí, AG	1
Shirodaria, C	1
Leeson, P	1
Antonopoulos, A	1
Warrick, N	1
Van-Assche, T	1
Cunnington, C	1
Pillai, R	1
Ratnatunga, C	1
Stefanadis, C	1
Channon, KM	1
Cottart, CH	1
Laguillier, C	1
Nivet-Antoine, V	1
Klimczak, C	1
Sebban, C	1
Beaudeux, JL	1
Landim, MB	1
Casella Filho, A	1
Chagas, AC	1
Pikula, A	1
Beiser, AS	1
DeCarli, C	1
Himali, JJ	1
Schulze, F	1
Au, R	1
Kelly-Hayes, M	1
Kase, CS	1
Wolf, PA	1
Seshadri, S	1
Li, Y	1
Zhao, A	1
Zeng, H	1
Lin, G	1
Jiang, H	1
Valtonen, P	1
Punnonen, K	1
Saarelainen, H	1
Heiskanen, N	1
Raitakari, OT	1
Juonala, M	1
Viikari, JS	1
Alfthan, G	1
Kähönen, M	1
Laaksonen, R	2
Lyyra-Laitinen, T	1
Laitinen, T	1
Heinonen, S	1
Kaygusuz, I	1
Turhan, NO	1
Duvan, CI	1
Koca, C	1
Aydin, M	1
Rodionov, RN	1
Murry, DJ	1
Vaulman, SF	1
Stevens, JW	1
Lentz, SR	1
Oyama, J	1
Maeda, T	1
Kouzuma, K	1
Ochiai, R	1
Tokimitsu, I	1
Higuchi, Y	1
Sugano, M	1
Makino, N	1
Cardounel, AJ	1
Pope, AJ	1
Heusinger-Ribeiro, J	1
Strobel, J	1
Jiang, B	1
Khandelwal, AR	1
Rogers, LK	1
Hebert, VY	1
Kleinedler, JJ	1
Zavecz, JH	1
Shi, W	1
Orr, AW	1
Dugas, TR	1
Atzeni, F	2
Turiel, M	2
Hollan, I	1
Meroni, P	1
Sitia, S	2
Tomasoni, L	2
Sarzi-Puttini, P	2

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Effect of Dexamethasone Implant on Retinal Nerve Fiber and Optic Disc Morphology in Patients With Diabetic Maculopathy[NCT03927118]		43 participants (Actual)	Observational	2018-02-01	Completed
Study for the Investigation of New Individual Risk Profiles and Therapeutic Strategies in Obesity Related Cardiovascular and Metabolic Disorders.[NCT00482924]		1,500 participants (Anticipated)	Observational	2003-01-31	Recruiting
Effect of Oral Supplementation With One Form of L-arginine on Vascular Endothelial Function in Healthy Subjects Featuring Risk Factors Related to the Metabolic Syndrome.[NCT02354794]		36 participants (Actual)	Interventional	2014-02-28	Completed
Characterization of the Metabolic Fate of an Oral L-arginine Form in Healthy Subjects Featuring Risk Factors Related to the Metabolic Syndrome.[NCT02352740]		32 participants (Actual)	Interventional	2013-03-31	Completed
LOVE-COARCT Study: Long-term Outcomes and Vascular Evaluation After Coarctation of the Aorta Treatment[NCT03262753]		90 participants (Anticipated)	Observational	2013-06-01	Recruiting
Influence of Preoperative Hemodialysis or Intraoperative Modified Ultrafiltration on Postoperative Outcome for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery: Randomized, Controlled, Multicenter Clinical Trial[NCT00720967]	Phase 3	450 participants (Anticipated)	Interventional	2008-11-30	Not yet recruiting
Effect of Beraprost Sodium on Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy (BESTinDN Study)[NCT01796418]		102 participants (Anticipated)	Interventional	2013-03-31	Recruiting
A Multicenter, Randomized Trial to Compare Xience and Vision Coronary Stents in the Same Multivessel Patient With Chronic Kidney Disease[NCT00818792]	Phase 2	215 participants (Actual)	Interventional	2009-01-31	Completed
Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients[NCT01157234]	Phase 4	32 participants (Actual)	Interventional	2010-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Absolute Change in Diastolic Blood Pressure (DBP), (millimeter, Mercury)= Month-12 sitting trough Diastolic Blood Pressure (millimeter, Mercury) level minus baseline sitting trough Diastolic Blood Pressure (millimeter, Mercury). (NCT01157234)
Timeframe: Change in Baseline, Month-12

Estimated Glomerular Filtration Rate (ml/Minute) Change From Baseline to Month-12 Between the Groups

Intervention	millimeter, mercury (Least Squares Mean)
Nebivolol	-0.66
Metoprolol	-2.35

The changed percentage in Estimated Glomerular Filtration Rate (eGFR), (based on the Modification of Diet in Renal Disease Equation)=[Month-12 GFR level minus baseline eGFR level] divided by [baseline eGFR level] multiplied by 100, where all levels are in ml/min. (NCT01157234)
Timeframe: Change in Baseline, Month-12

Mean Arterial Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 Between the Groups

Intervention	percent change (Least Squares Mean)
Nebivolol	2.16
Metoprolol	10.43

"Absolute change in Mean Arterial Blood Pressure, (MAP), (millimeter, Mercury= Month-12 sitting trough MAP minus baseline sitting trough MAP.~Mean Arterial Pressure= 2/3 trough diastolic blood pressure + 1/3 trough systolic blood pressure" (NCT01157234)
Timeframe: Change in Baseline, Month-12

Number of Antihypertensive Drug Classes Change From Baseline to Month-12 Between the Groups.

Intervention	millimeter, Mercury (Least Squares Mean)
Nebivolol	-1.07
Metoprolol	-3.19

Percent change in quantity of Anti-Hypertensive Drug Classes (AHDC)=[Month-12 absolute number of AHDC minus baseline absolute number of AHDC] divided by [baseline absolute number of AHDC] multiplied by 100. (NCT01157234)
Timeframe: Change in Baseline, Month-12

Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients < 50 Years Old Compared With Metoprolol in Transplant Recipients < 50 Years Old

Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients <50 Years Old Compared With Metoprolol in Transplant Recipients >/= 50 Years Old.

Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients >/= 50 Years Old Compared With Metoprolol in Transplant Recipients Age >/= 50 Years Old.

Percent Change in Plasma Nitric Oxide Level From Baseline to Month-twelve of Treatment With Nebivolol in Transplant Recipients >/= 50 Years Old Compared With Nebivolol in Transplant Recipients < 50 Years Old.

Plasma Nitric Oxide Level (Nmol/L) at Month-12 Between the Groups.

Plasma Nitric Oxide Level Change From Baseline to Month 12 Between the Groups.

Intervention	percent change (Least Squares Mean)
Nebivolol	-8.14
Metoprolol	8.70

Intervention	percent change (Least Squares Mean)
Nebivolol < 50 Years Old	51.55
Metoprolol <50 Years Old	-16.64

Intervention	percent change (Least Squares Mean)
Nebivolol <50 Year Old	51.55
Metoprolol >/= 50 Year Old	-17.99

Intervention	percent change (Least Squares Mean)
Nebivolol >/=50 Years Old	-15.25
Metoprolol >/=50 Years Old	-17.99

Intervention	percent change (Least Squares Mean)
Nebivolol >/=50 Years Old	-15.25
Metoprolol <50 Years Old	-16.64

Intervention	nmol/L (Least Squares Mean)
Nebivolol	50.07
Metoprolol	38.13

Percent change in Nitric Oxide (NO) blood level (nmol/L)=[Month-12 NO blood level minus baseline NO blood level] divided by [baseline NO blood level] multiplied by 100, where all levels are in nmol/L. (NCT01157234)
Timeframe: Change in Baseline, Month-12

Systolic Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 of Treatment Between the Groups

Intervention	percent change (Least Squares Mean)
Nebivolol	11.47
Metoprolol	-17.27

Absolute change in Systolic Blood Pressure (SBP), (millimeter, Mercury)=Month-12 sitting trough SBP level minus baseline sitting trough SBP level (NCT01157234)
Timeframe: Change in Baseline, Month-12

Article	Year
Asymmetric Dimethylarginine as a Biomarker in Coronary Artery Disease. Current topics in medicinal chemistry, 2023, Volume: 23, Issue:6 Topics: Arginine; Atherosclerosis; Biomarkers; Coronary Artery Disease; Humans; Risk Factors	2023
Asymmetric Dimethylarginine as a Biomarker in Coronary Artery Disease. Current topics in medicinal chemistry, 2023, Volume: 23, Issue:6 Topics: Arginine; Atherosclerosis; Biomarkers; Coronary Artery Disease; Humans; Risk Factors	2023
Asymmetric Dimethylarginine as a Biomarker in Coronary Artery Disease. Current topics in medicinal chemistry, 2023, Volume: 23, Issue:6 Topics: Arginine; Atherosclerosis; Biomarkers; Coronary Artery Disease; Humans; Risk Factors	2023
Asymmetric Dimethylarginine as a Biomarker in Coronary Artery Disease. Current topics in medicinal chemistry, 2023, Volume: 23, Issue:6 Topics: Arginine; Atherosclerosis; Biomarkers; Coronary Artery Disease; Humans; Risk Factors	2023
The role of asymmetric dimethylarginine in endothelial dysfunction and abnormal nitric oxide metabolism in systemic sclerosis: results from a pilot study. Clinical rheumatology, 2023, Volume: 42, Issue:4 Topics: Adult; Aged; Arginine; Atherosclerosis; Biomarkers; Carotid Intima-Media Thickness; Cross-Sectional	2023
Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023, Nov-30, Volume: 38, Issue:12 Topics: Arginine; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; D	2023
Assessment of Endothelial Dysfunction with Methylated Arginines and L-arginine in Cadmium-Exposed People: a Pilot Study. Clinical laboratory, 2019, Oct-01, Volume: 65, Issue:10 Topics: Adult; Arginine; Atherosclerosis; Cadmium; Chromatography, Liquid; Endothelium, Vascular; Environmen	2019
Dihydromyricetin increases endothelial nitric oxide production and inhibits atherosclerosis through microRNA-21 in apolipoprotein E-deficient mice. Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:10 Topics: Amidohydrolases; Animals; Apolipoproteins E; Arginine; Atherosclerosis; Enzyme Activation; Flavonols	2020
Lack of evidence of the correlation between plasma Asymmetrical Dimethylarginine correlation and IMT in type 2 diabetic patients with chronic vascular complication. Acta biochimica Polonica, 2021, Feb-05, Volume: 68, Issue:1 Topics: Adult; Aged; Arginine; Atherosclerosis; Carotid Artery, Internal; Carotid Intima-Media Thickness; Ca	2021
Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine/dimethylarginine dimethylaminotransferase 2 pathway. Redox biology, 2021, Volume: 46 Topics: Amidohydrolases; Animals; Arginine; Atherosclerosis; Endothelial Cells; Humans; Hyperuricemia; Mice;	2021
Independent Association of Plasma Hydroxysphingomyelins With Physical Function in the Atherosclerosis Risk in Communities (ARIC) Study. The journals of gerontology. Series A, Biological sciences and medical sciences, 2018, 07-09, Volume: 73, Issue:8 Topics: Aged; Arginine; Atherosclerosis; Cross-Sectional Studies; Female; Hand Strength; Humans; Linear Mode	2018
Effects of betaine supplementation on nitric oxide metabolism, atherosclerotic parameters, and fatty liver in guinea pigs fed a high cholesterol plus methionine diet. Nutrition (Burbank, Los Angeles County, Calif.), 2018, Volume: 45 Topics: Animals; Arginine; Atherosclerosis; Betaine; Cholesterol; Cholesterol, Dietary; Diet, High-Fat; Diet	2018
Anti-Atherogenic Activity of Polyphenol-Rich Extract from Bee Pollen. Nutrients, 2017, Dec-18, Volume: 9, Issue:12 Topics: Angiotensin II; Animals; Arginine; Atherosclerosis; Bees; Cholesterol; Coronary Artery Disease; Diet	2017
Asymmetric dimethylarginine levels and diabetes duration: Relationship with measures of subclinical atherosclerosis and cardiac function in children and adolescents with Type 1 diabetes. Diabetes & vascular disease research, 2018, Volume: 15, Issue:3 Topics: Adolescent; Adult; Arginine; Atherosclerosis; Carotid Intima-Media Thickness; Child; Diabetes Mellit	2018
Endothelium, asymmetric dimethylarginine, and atherosclerosis in chronic kidney disease. Polish archives of internal medicine, 2018, 03-29, Volume: 128, Issue:3 Topics: Arginine; Atherosclerosis; Endothelium; Humans; Radial Artery; Renal Insufficiency, Chronic	2018
Serum ADMA, endothelial dysfunction, and atherosclerosis in hypervolemic \ hemodialysis patients Turkish journal of medical sciences, 2018, Oct-31, Volume: 48, Issue:5 Topics: Arginine; Atherosclerosis; C-Reactive Protein; Carotid Intima-Media Thickness; Cohort Studies; Echoc	2018
The iridoid loganic acid and anthocyanins from the cornelian cherry (Cornus mas L.) fruit increase the plasma l-arginine/ADMA ratio and decrease levels of ADMA in rabbits fed a high-cholesterol diet. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2019, Volume: 52 Topics: Amidohydrolases; Animals; Anthocyanins; Arginine; Atherosclerosis; Cholesterol, Dietary; Citrulline;	2019
Increased asymmetric dimethylarginine in vitamin B12 deficient adolescents. Cardiology in the young, 2019, Volume: 29, Issue:2 Topics: Adolescent; Arginine; Atherosclerosis; Biomarkers; Carotid Arteries; Carotid Intima-Media Thickness;	2019
Comparison of plasma viscosity as a marker of endothelial dysfunction with nitric oxide and asymmetric dimethylarginine in subjects with dyslipidemia. Clinical hemorheology and microcirculation, 2014, Volume: 57, Issue:4 Topics: Adult; Aged; Arginine; Atherosclerosis; Biomarkers; Blood Viscosity; Dyslipidemias; Endothelium, Vas	2014
Carotid intima-media thickness and plasma asymmetric dimethylarginine in Mexican children exposed to inorganic arsenic. Environmental health perspectives, 2013, Volume: 121, Issue:9 Topics: Adolescent; Arginine; Arsenic; Atherosclerosis; Biomarkers; Carotid Intima-Media Thickness; Child; C	2013
Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction. Diabetes & vascular disease research, 2013, Volume: 10, Issue:5 Topics: Aged; Amidohydrolases; Arginine; Atherosclerosis; Cells, Cultured; Diabetic Nephropathies; Endotheli	2013
Association between endothelial dysfunction and frailty: the Toledo Study for Healthy Aging. Age (Dordrecht, Netherlands), 2014, Volume: 36, Issue:1 Topics: Aged; Arginine; Atherosclerosis; Biomarkers; Comorbidity; Demography; Female; Frail Elderly; Geriatr	2014
Relationship between serum paraoxonase and homocysteine thiolactonase activity, adipokines, and asymmetric dimethyl arginine concentrations in renal transplant patients. Transplantation proceedings, 2013, Volume: 45, Issue:10 Topics: Adipokines; Adult; Aged; Arginine; Aryldialkylphosphatase; Atherosclerosis; Biomarkers; C-Reactive P	2013
[Effect of crucumin on vascular endothelial function in atherosclerotic rabbits]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2013, Volume: 38, Issue:19 Topics: Animals; Arginine; Atherosclerosis; Curcumin; Endothelium, Vascular; Male; Nitric Oxide Synthase; Ra	2013
Effect of lowering asymmetric dimethylarginine (ADMA) on vascular pathology in atherosclerotic ApoE-deficient mice with reduced renal mass. International journal of molecular sciences, 2014, Mar-31, Volume: 15, Issue:4 Topics: Amidohydrolases; Animals; Aorta; Apolipoproteins E; Arginine; Atherosclerosis; Disease Models, Anima	2014
Relation of asymmetric dimethylarginine levels to macrovascular disease and inflammation markers in type 2 diabetic patients. Journal of diabetes research, 2014, Volume: 2014 Topics: Aged; Arginine; Atherosclerosis; Biomarkers; Blood Sedimentation; C-Reactive Protein; Carotid Intima	2014
Asymmetric dimethylarginine is associated with carotid atherosclerosis in patients with essential hypertension. Clinical and experimental hypertension (New York, N.Y. : 1993), 2015, Volume: 37, Issue:5 Topics: Arginine; Atherosclerosis; Biomarkers; Blood Pressure; Carotid Artery Diseases; Carotid Artery, Comm	2015
Plasma arginine/ADMA ratio as a sensitive risk marker for atherosclerosis: Shimane CoHRE study. Atherosclerosis, 2015, Volume: 239, Issue:1 Topics: Aged; Arginine; Atherosclerosis; Biomarkers; Blood Pressure; Body Mass Index; Carotid Arteries; Caro	2015
Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity. Rheumatology international, 2015, Volume: 35, Issue:8 Topics: Adult; Arginine; Arthritis, Psoriatic; Asymptomatic Diseases; Atherosclerosis; Brachial Artery; Card	2015
Hyperhomocysteinemia: a missing link to dysfunctional HDL via paraoxanase-1. Canadian journal of physiology and pharmacology, 2015, Volume: 93, Issue:9 Topics: Amidohydrolases; Animals; Arginine; Aryldialkylphosphatase; Atherosclerosis; Blood Pressure; Connexi	2015
Methylarginines in Mice with Experimental Atherosclerosis. Bulletin of experimental biology and medicine, 2015, Volume: 160, Issue:1 Topics: Animals; Arginine; Atherosclerosis; Cholesterol; Endothelium, Vascular; Male; Mice; Mice, Inbred CBA	2015
L-Arginine Derivatives Are Associated with the Hyperthyroid State in the General Population. Thyroid : official journal of the American Thyroid Association, 2016, Volume: 26, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Arginine; Atherosclerosis; Cross-Sectional Studies; Female; Germany;	2016
[THE CLINICAL LABORATORY MARKERS OF ATHEROSCLEROSIS IN PATIENTS WITH ATHEROTHROMBOTIC STROKE]. Klinicheskaia laboratornaia diagnostika, 2015, Volume: 60, Issue:10 Topics: Aged; Aged, 80 and over; Arginine; Atherosclerosis; Biomarkers; C-Reactive Protein; Carotid Stenosis	2015
N-methylnicotinamide protects against endothelial dysfunction and attenuates atherogenesis in apolipoprotein E-deficient mice. Molecular nutrition & food research, 2016, Volume: 60, Issue:7 Topics: Acetylcholine; Amidohydrolases; Animals; Aorta; Arginine; Atherosclerosis; Cholesterol, Dietary; Cyc	2016
Soluble receptor and gene polymorphism for AGE: relationship with obesity and cardiovascular risks. Pediatric research, 2016, Volume: 80, Issue:1 Topics: Adolescent; Alleles; Arginine; Atherosclerosis; Biomarkers; Blood Pressure; Cardiovascular Diseases;	2016
ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2016, Volume: 22, Issue:9 Topics: Adult; Ankle Brachial Index; Arginine; Atherosclerosis; Biomarkers; C-Reactive Protein; Carotid Inti	2016
Marker of Endothelial Dysfunction Asymmetric Dimethylarginine Is Elevated in HIV Infection but Not Associated With Subclinical Atherosclerosis. Journal of acquired immune deficiency syndromes (1999), 2016, Dec-15, Volume: 73, Issue:5 Topics: Adult; Arginine; Atherosclerosis; Biomarkers; Cross-Sectional Studies; Endothelial Cells; Female; HI	2016
The prediction roles of asymmetric dimethyl-arginine, adiponectin and apelin for macroangiopathy in patients with impaired glucose regulation. Annales d'endocrinologie, 2016, Volume: 77, Issue:6 Topics: Adiponectin; Aged; Apelin; Arginine; Atherosclerosis; Blood Glucose; Coronary Disease; Female; Gluco	2016
Evaluation of endothelial dysfunction in patients with familial Mediterranean fever: the relationship between the levels of asymmetric dimethylarginine and endocan with carotid intima-media thickness and endothelium-dependent vasodilation. Clinical rheumatology, 2017, Volume: 36, Issue:9 Topics: Adult; Arginine; Atherosclerosis; Biomarkers; Carotid Intima-Media Thickness; Case-Control Studies;	2017
Increased brachial intima-media thickness is associated with circulating levels of asymmetric dimethylarginine in patients with COPD. International journal of chronic obstructive pulmonary disease, 2017, Volume: 12 Topics: Aged; Arginine; Asymptomatic Diseases; Atherosclerosis; Biomarkers; Brachial Artery; Case-Control St	2017
The role of L-arginine/L-homoarginine/nitric oxide pathway for aortic distensibility and intima-media thickness in stroke patients. Amino acids, 2017, Volume: 49, Issue:6 Topics: Aorta; Arginine; Atherosclerosis; Endothelium, Vascular; Female; Homoarginine; Humans; Male; Middle	2017
Asymmetric dimethylarginine (ADMA) is tightly correlated with growth in juveniles without correlations to obesity related disorders. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2008, Volume: 116, Issue:9 Topics: Adolescent; Alkaline Phosphatase; Arginine; Atherosclerosis; Blood Pressure; Body Mass Index; Child;	2008
Evaluation of the relationship between flow-mediated vasodilation and some atherogenic risk markers in severe hypercholesterolemia. Folia medica, 2008, Volume: 50, Issue:1 Topics: Arginine; Atherosclerosis; Biomarkers; Cholesterol, LDL; Humans; Hypercholesterolemia; Risk Factors;	2008
[Asymmetric dimethil-arginine (ADMA) as a link between insulin resistance and atherosclerosis]. Ideggyogyaszati szemle, 2008, May-30, Volume: 61, Issue:5-6 Topics: Adult; Arginine; Atherosclerosis; Cardiovascular Diseases; Carotid Stenosis; Chromatography; Enzyme	2008
Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. American journal of nephrology, 2009, Volume: 29, Issue:1 Topics: Aged; Aorta; Arginine; Arteries; Atherosclerosis; B-Lymphocytes; Body Mass Index; C-Reactive Protein	2009
Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: six-year prospective study using carotid ultrasonography. Hypertension research : official journal of the Japanese Society of Hypertension, 2008, Volume: 31, Issue:6 Topics: Aged; Arginine; Atherosclerosis; Carotid Arteries; Disease Progression; Female; Humans; Linear Model	2008
Increased plasma levels of asymmetric dimethylarginine and soluble CD40 ligand in patients with sleep apnea. Respiration; international review of thoracic diseases, 2009, Volume: 77, Issue:1 Topics: Adult; Arginine; Atherosclerosis; Cardiovascular Diseases; Case-Control Studies; CD40 Ligand; Endoth	2009
Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. European heart journal, 2009, Volume: 30, Issue:9 Topics: Aged; Arginine; Atherosclerosis; Coronary Artery Bypass; Coronary Artery Disease; Endothelium, Vascu	2009
Association of plasma ADMA levels with MRI markers of vascular brain injury: Framingham offspring study. Stroke, 2009, Volume: 40, Issue:9 Topics: Adult; Aged; Arginine; Atherosclerosis; Biomarkers; Brain; Brain Infarction; Cohort Studies; Endothe	2009
[Effects of Xuefu Zhuyu decoction on serum asymmetric dimethylarginine in atherosclerosis rabbits]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2009, Volume: 34, Issue:12 Topics: Animals; Arginine; Atherosclerosis; Cholesterol; Disease Models, Animal; Drugs, Chinese Herbal; Huma	2009
ADMA concentration changes across the menstrual cycle and during oral contraceptive use: the Cardiovascular Risk in Young Finns Study. European journal of endocrinology, 2010, Volume: 162, Issue:2 Topics: Adult; Arginine; Atherosclerosis; Brachial Artery; C-Reactive Protein; Contraceptives, Oral; Creatin	2010
Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. The Journal of biological chemistry, 2010, Feb-19, Volume: 285, Issue:8 Topics: Adenoviridae; Animals; Arginine; Atherosclerosis; Chlorocebus aethiops; Citrulline; COS Cells; Diabe	2010
Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine. The American journal of pathology, 2010, Volume: 176, Issue:5 Topics: Amidohydrolases; Animals; Aorta; Apolipoproteins E; Arginine; Atherosclerosis; Blood Pressure; Cardi	2010
Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia. Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 117, Issue:2 Topics: Animals; Anti-HIV Agents; Arginine; Atherosclerosis; Biomarkers; Cell Proliferation; Drug Therapy, C	2010
Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study. Clinical rheumatology, 2011, Volume: 30, Issue:1 Topics: Adult; Arginine; Arteries; Atherosclerosis; Carotid Artery, Common; Cross-Sectional Studies; Electro	2011
Asymmetric dimethylarginine and vascular indices of atherosclerosis in patients after coarctation of aorta repair. International journal of cardiology, 2012, Jul-26, Volume: 158, Issue:3 Topics: Adult; Aortic Coarctation; Arginine; Atherosclerosis; Biomarkers; Blood Flow Velocity; C-Reactive Pr	2012
Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. The Journal of rheumatology, 2011, Volume: 38, Issue:8 Topics: Adult; Aged; Arginine; Arthritis, Psoriatic; Atherosclerosis; Biomarkers; Carotid Artery, Common; Co	2011
Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine, 2013, Volume: 43, Issue:1 Topics: Adult; Arginine; Atherosclerosis; Brachial Artery; Carotid Arteries; Carotid Intima-Media Thickness;	2013
Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. Clinical endocrinology, 2013, Volume: 78, Issue:5 Topics: Adiponectin; Adult; alpha-2-HS-Glycoprotein; Arginine; Atherosclerosis; Carotid Artery Diseases; Car	2013
Do cardiac risk factors affect the homocysteine and asymmetric dimethylarginine relationship in patients with coronary artery diseases? Clinical biochemistry, 2012, Volume: 45, Issue:16-17 Topics: Adult; Aged; Arginine; Atherosclerosis; Coronary Artery Disease; Female; Homocysteine; Humans; Male;	2012
Assessment of atherosclerosis risk due to the homocysteine-asymmetric dimethylarginine-nitric oxide cascade in children taking antiepileptic drugs. Seizure, 2013, Volume: 22, Issue:2 Topics: Adolescent; Anticonvulsants; Arginine; Atherosclerosis; Biomarkers; Carbamazepine; Child; Epilepsy;	2013
Asymmetric dimethylarginine: a molecule responsible for the coexistence of insulin resistance and atherosclerosis via dual nitric oxide synthase inhibition. Medical hypotheses, 2005, Volume: 65, Issue:6 Topics: Animals; Arginine; Atherosclerosis; Biomarkers; Enzyme Inhibitors; Evidence-Based Medicine; Humans;	2005
Effects of ADMA upon gene expression: an insight into the pathophysiological significance of raised plasma ADMA. PLoS medicine, 2005, Volume: 2, Issue:10 Topics: Arginine; Atherosclerosis; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein Receptors, Type	2005
Elevated serum interleukin-18 levels might reflect the high risk of hospitalization in patients on peritoneal dialysis. Nephrology (Carlton, Vic.), 2005, Volume: 10, Issue:6 Topics: Aged; Arginine; Atherosclerosis; beta 2-Microglobulin; Biomarkers; Female; Hospitalization; Humans;	2005
Atherosclerosis and the Glu298Asp polymorphism of the eNOS gene in white patients with end-stage renal disease. American journal of hypertension, 2005, Volume: 18, Issue:12 Pt 1 Topics: Aged; Arginine; Atherosclerosis; Carotid Arteries; Carotid Artery Diseases; Female; Gene Frequency;	2005
Treatment with niacin lowers ADMA. Atherosclerosis, 2006, Volume: 184, Issue:2 Topics: Adult; Aged; Arginine; Atherosclerosis; Biomarkers; Female; Humans; Hypolipidemic Agents; Male; Midd	2006
Plasma asymmetric dimethylarginine (ADMA), nitrate and the indices of low-density lipoprotein oxidation. Clinica chimica acta; international journal of clinical chemistry, 2006, Volume: 371, Issue:1-2 Topics: Adult; Aged; Arginine; Atherosclerosis; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lipid Met	2006
Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. American journal of hypertension, 2006, Volume: 19, Issue:5 Topics: Arginine; Atherosclerosis; Biomarkers; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Imm	2006
Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2006, Volume: 48, Issue:5 Topics: Arginine; Atherosclerosis; Cardiovascular Diseases; Comorbidity; Female; Homocysteine; Humans; Kidne	2006
Vaso-occlusion in Schimke-immuno-osseous dysplasia: is the NO pathway involved? Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2006, Volume: 38, Issue:10 Topics: Adolescent; Adult; Arginine; Arterial Occlusive Diseases; Atherosclerosis; Child; Child, Preschool;	2006
Dimethylarginines at the crossroad of insulin resistance and atherosclerosis. Metabolism: clinical and experimental, 2007, Volume: 56, Issue:3 Topics: Adult; Arginine; Atherosclerosis; Female; Humans; Insulin Resistance; Male; Middle Aged	2007
Serum asymmetric dimethylarginine negatively correlates with intima-media thickness in early-onset atherosclerosis. Cerebrovascular diseases (Basel, Switzerland), 2007, Volume: 23, Issue:5-6 Topics: Age of Onset; Arginine; Atherosclerosis; Biomarkers; Carotid Artery, Internal; Carotid Stenosis; Cas	2007
Presence of asymmetric dimethylarginine gradients across high-grade lesions in patients with coronary artery disease. Coronary artery disease, 2007, Volume: 18, Issue:6 Topics: Aged; Angioplasty, Balloon, Laser-Assisted; Arginine; Atherosclerosis; Biomarkers; Coronary Artery D	2007
Oxidative stress in cardiovascular disease: successful translation from bench to bedside? Circulation, 2007, Sep-18, Volume: 116, Issue:12 Topics: Arginine; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Endothelium, Vascular; Hemorheology;	2007

n(g),n(g')-dimethyl-l-arginine and Atherogenesis